

**Adult Brain Tumor Consortium
(ABTC)**
Central Office:
Johns Hopkins
David H. Koch Cancer Research Building
1550 Orleans Street, Suite 1M-16
Baltimore, MD 21231-1000
410-955-3657 T
410-614-9335 F

Stuart Grossman, MD
Co-Director
Michael Prados, MD
Co-Director
Joy Fisher, MA, CCRP
Manager



December 17th, 2012

Joseph Elliot, Ph.D.
Managing Director
Epitopoietic Research Corporation (ERC)
1055 E Colorado Blvd., Suite 500
Pasadena, CA 91106 USA

Dear Joe:

It was a pleasure to have met you and to have had ERC's presentation at the NIH funded Adult Brain Tumor Consortium (ABTC) meeting in Baltimore on December 10, 2012. As discussed, the ABTC is very interested in working with companies like ERC which have highly promising novel therapies for brain cancer, particularly high grade gliomas. The ABTC member institutions represent the leading clinical and academic institutions with active brain cancer centers in the United States. We can offer involvement of member institutions in early stage clinical trials and provide unique support in terms of institutional support (investigators, research nursing, and data management), trial design, clinical specimen monitoring and biomarker analysis .

I sincerely hope that the ABTC and ERC will be working together on a vaccine protocol in the near future.

Yours truly,



Stuart A. Grossman, MD
Principal Investigator
Adult Brain Tumor Consortium (ABTC)
Professor of Oncology, Medicine & Neurosurgery
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cancer Research Building #2, Suite 1M-16
1550 Orleans Street
Baltimore, MD 21231